
Bristol Myers Squibb reports updated findings from the Phase 3 COMMANDS trial at the 2023 ASH Annual Meeting, reaffirming the superior efficacy and longer durability of Reblozyl (luspatercept-aamt) compared to epoetin alfa in ESA-naïve patients with lower-risk MDS. Results indicate a 60.4% RBC transfusion independence rate with Reblozyl versus 34.8% with epoetin alfa. The data support Reblozyl's potential as a transformative treatment for anemia associated with MDS. Safety results align with previous MDS studies. Reblozyl is currently under review by the European Commission and received priority approval from the FDA in August 2023.
Like
Save
Share